BCL2 and diffuse large B-cell lymphoma: With durable remission achieved in 50%–60% of the patients upon immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), the prognosis of DLBCL patients is impacted by multiple factors, including cell-of-origin (COO), BCL-2/MYC double expression (DEL), and double hit lymphoma (DHL).